Palivizumab coverage rates among moderate-to-late preterm infants in Korea: a nationwide cross-sectional study
In the initial 3 RSV seasons following the introduction of palivizumab reimbursement for MLPT infants in Korea, the overall coverage rate was low (42.2%). National policies targeting infants with higher gestational ages, those born in March, and those residing in non-capital areas are necessary to improve coverage and ensure equitable RSV prophylaxis.
Authors
- Saram Lee (ORCID: https://orcid.org/0000-0002-2441-8052)
- Ju Sun Heo (ORCID: https://orcid.org/0000-0001-8928-289X)
- Young June Choe (ORCID: https://orcid.org/0000-0003-2733-0715)
- Seungyeon Kim (ORCID: https://orcid.org/0000-0001-6708-5684)
Institutions
- Seoul National University (KR)
- Korea University Medical Center (KR)
- Seoul National University Hospital (KR)
- Seoul National University Children's Hospital (KR)
- Dankook University (KR)
Publication Details
- Journal
- Epidemiology and Health
- Published
- 2025-03-31
- DOI
- https://doi.org/10.4178/epih.e2025015
- Primary Topic
- Neonatal Respiratory Health Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00